{"paper_id":"6c7e6f6c-b700-4a50-80a3-9f42fd5f0702","body_text":"Comment on “Endometriosis and Ovarian Cancer Risk”\n- Linda Van Lea\nAn estimated 10% of reproductive-aged women are affected by endometriosis, a chronic, estrogen-dependent gynecologic disorder characterized by ectopic endometrial-like implants displaced in nonuterine locations throughout the pelvis. Although this condition is not malignant, it does have cancer-like traits and potential for malignant transformation. Both epidemiological and molecular evidence support this association for ovarian cancer, though the absolute risk of ovarian cancer for patients with endometriosis remains low.\nA systematic literature review was conducted to assess current medical literature on the oncological risk associated with endometriosis. Databases included PubMed, Scopus, and Web of Science. Inclusion criteria for studies were publication date between January 1, 2000, and October 1, 2025, and pertinent reporting of outcomes. Studies focusing on the epidemiology of ovarian cancer consistently report a moderately elevated risk of the disease in patients with endometriosis, particularly in endometrioid and clear cell subtypes. Most epidemiological studies on this topic have been retrospective case-control or cohort studies, which must be interpreted carefully due to inherent bias in study design. Meta-analyses have shown similar findings. Though prospective data are limited, studies that do exist report similar findings, with the addition of an even greater elevated risk for patients with deep infiltrating endometriosis and ovarian endometriomas. However, there is an overall lack of generalizability in epidemiologic studies due to heterogeneity in the definitions of endometriosis across studies.\nRecent evidence has shown that certain types of endometriosis, such as deep infiltrating endometriosis or ovarian endometriomas, are associated with a 9.66-fold increase in developing ovarian cancer. More severe forms of endometriosis also tend to be more associated with the endometrioid and clear cell ovarian cancer subtypes, likely due to the mechanisms of chronic inflammation, oxidative stress, and immune dysregulation that accompany the more severe forms.\nOne of the central mechanisms of endometriosis is chronic inflammation, which creates the potential for malignant transformation. Inflammatory mediators initiate a cascade of oxidative stress, genomic instability, and dysregulated cell proliferation that contributes to the development of malignancy. Ferroptosis is a regulated form of cell death driven by iron overload and lipid peroxidation. Studies suggest that ferroptosis resistance in epithelial cells and its activation in stromal cells contribute to malignant transformation in patients with endometriosis. Recent studies show that there is significant overlap in genetic and molecular elements of endometriosis and ovarian cancer.\nThe management of endometriosis requires monitoring, particularly in women who have been diagnosed for long periods of time, those who have atypical endometriosis, or those who have large endometriomas. Universally accepted screening for ovarian cancer is not effective, which presents a challenge for early detection in patients with possible elevated risk. The current methods for diagnosis and evaluation of endometriosis have low sensitivity for ovarian cancer in the early stages, which underscores a need for better biomarkers and tools with greater sensitivity for both endometriosis and ovarian cancer. Significant opportunities remain for targeted therapies, though the translation into clinical practice presents a challenge. Ongoing studies are exploring treatments for ovarian cancers that can also address endometriosis-related malignancy, though each still requires further clinical validation before introducing them to clinical practice. Standardizing guidelines that reflect the known risks of ovarian cancer in women with endometriosis to assist in early detection is recommended.\n(Summarized from Bogani G, Moore KN, Ray-Coquard I, et al. Endometriosis and ovarian cancer risk. Gynecol Oncol. 2026;209:88-98. doi:10.1016/j.ygyno.2026.05.004).","source_license":"CC0","license_restricted":false}